Advanced Body Recomposition Stack

The Advanced Body Recomposition Stack pairs tirzepatide (dual GLP-1/GIP agonist) with CJC-1295/Ipamorelin (GH secretagogue stack) to achieve simultaneous fat loss and lean mass gain — creating the conditions for true body recomposition rather than simple weight loss. Tirzepatide drives aggressive fat loss through the strongest dual-agonist mechanism available: GLP-1 receptor suppression of appetite combined with GIP receptor enhancement of fat oxidation and insulin sensitivity. In the SURMOUNT trials, tirzepatide at 15mg/week produced 22.5% body weight loss — predominantly from fat, with preservation of lean mass. CJC-1295/Ipamorelin provides the anabolic counterbalance: by stimulating natural pulsatile GH release, the GH secretagogue stack increases IGF-1 levels, promotes satellite cell activation, and enhances protein synthesis — creating an anabolic signal that preferentially builds lean mass while tirzepatide's caloric deficit drives fat mobilization. The metabolic result is what practitioners call a "body composition favorable environment": simultaneous caloric deficit combined with elevated anabolic signaling that instructs the body to oxidize fat stores while maintaining or increasing lean tissue.